Integrated Treatment for Smoking Cessation After Acute Coronary Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
Summary of the Project :Quitting smoking following acute coronary syndrome (ACS) can reduce mortality up to 50%. However, depression and smoking are highly co-morbid and depressed mood may interfere with cessation and independently predicts mortality. Thus, a single, integrated treatment for both smoking and depression could be highly effective in reducing post-acute coronary syndrome mortality. Behavioral Activation (BA) is a well established treatment for depression and has recently shown promise as a treatment for smoking cessation. The investigators systematically developed an intervention integrating gold standard smoking cessation counseling with existing BA based mood management techniques for post-ACS smokers; Behavioral Activation Treatment for Cardiac Smokers (BAT-CS).Objective: For this R01 the investigators will evaluate the efficacy of using a single, integrated treatment that targets both depressed mood and smoking (BAT-CS).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, it does require that you are not currently attending counseling for depression or smoking cessation.
Is the integrated treatment for smoking cessation after acute coronary syndrome safe?
What makes the BAT-CS treatment unique for smoking cessation after acute coronary syndrome?
What data supports the effectiveness of the treatment BAT-CS for smoking cessation after acute coronary syndrome?
Research shows that combining smoking cessation counseling with mood management, like in the BAT-CS treatment, can help people quit smoking after a heart event. Behavioral interventions have been found to improve smoking abstinence rates at 6 and 12 months, although more research is needed to confirm these findings.237910
Who Is on the Research Team?
Andrew Busch, PhD
Principal Investigator
Senior Investigator
Are You a Good Fit for This Trial?
This trial is for hospital inpatients aged 18-75 who had an acute coronary syndrome (ACS) event within the last month, smoke at least one cigarette daily before hospitalization, speak English, are considering quitting smoking after discharge, and can use a phone. It's not for those with severe mental illness or high risk of dying within six months.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Behavioral Activation Treatment for Cardiac Smokers (BAT-CS) or control condition for 12 weeks, focusing on smoking cessation and mood management
Follow-up
Participants are monitored for smoking abstinence, depression symptoms, and major adverse cardiac events
Long-term follow-up
Tracking of major adverse cardiac events and all-cause mortality
What Are the Treatments Tested in This Trial?
Interventions
- BAT-CS
- Smoking Cessation and Health & Wellness
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hennepin Healthcare Research Institute
Lead Sponsor
Minneapolis Heart Institute Foundation
Collaborator
The Miriam Hospital
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
University of Minnesota
Collaborator